| Title: | A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes |
| Journal: | Med |
| Published: | 1 Jul 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/34258604/ |
| DOI: | https://doi.org/10.1016/j.medj.2021.04.011 |
| URL: | https://www.cell.com/article/S2666634021001604/pdf |
Publication 13795
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: A coding variant in MTARC1 (rs2642438; p.Ala165Thr) was recently associated with protection from cirrhosis in European individuals. However, its impact on overall and cause-specific mortality remained elusive.</p>
METHODS: Using a genome-first approach, we explored a range of metabolic phenotypes and outcomes associated with MTARC1 p.Ala165Thr in the UKBiobank and the Penn-Medicine BioBank.</p>
FINDINGS: MTARC1 p.Ala165Thr was significantly associated with higher triglycerides, lower total cholesterol, lower LDL-C, lower ApoB, lower HDL-C, lower ApoA-I and higher IGF-1. Per each minor allele, the risk of NAFLD was reduced by ~15%. The ALT-lowering and NAFLD-protective effect of MTARC1 p.Ala165Thr was amplified by obesity, diabetes mellitus and presence of PNPLA3 rs738409:G. In African-American and Black-British individuals, the allele frequency of MTARC1 p.Ala165Thr was lower, but carriers showed the same distinctive lipid phenotype. Importantly, MTARC1 p.Ala165Thr carriers did not show higher cardiovascular disease burden as evidenced by cardiac MRI and carotid ultrasound. In prospective analyses, the homozygous minor allele was associated with up to 39% lower rates of liver-related mortality, while no risk of increased overall or cardiovascular death could be observed. Strikingly, liver-related mortality was more than 50% reduced in diabetic participants or carriers of PNPLA3 rs738409:G.</p>
CONCLUSIONS: Together these data highlight MTARC1 as an important liver disease modifier that influences plasma lipids in an allele-dose-dependent manner without increasing cardiovascular outcomes. Our results point toward potential mechanisms and reveal a remarkable association with liver-related mortality calling for future studies exploring its therapeutic potential.</p>
FUNDING: This study was funded by the German Research Foundation (DFG).</p>
11 Keywords
- Heterozygote
- Homozygote
- Humans
- Lipase
- Membrane Proteins
- Mitochondrial Proteins
- Non-alcoholic Fatty Liver Disease
- Oxidoreductases
- Phenotype
- Polymorphism, Single Nucleotide
- Prospective Studies
13 Authors
- Carolin V Schneider
- Kai Markus Schneider
- Donna M Conlon
- Joseph Park
- Marijana Vujkovic
- Inuk Zandvakili
- Yi-An Ko
- Christian Trautwein
- Regerneron Center
- Rotonya M Carr
- Pavel Strnad
- Christoph A Thaiss
- Daniel J Rader
1 Application
| Application ID | Title |
|---|---|
| 59657 | Regulators of metabolic co-morbidities |
Enabling scientific discoveries that improve human health